Last reviewed · How we verify
SCH-58235
SCH-58235 is a selective endothelin receptor antagonist that blocks endothelin-1 signaling to reduce pulmonary vascular resistance and improve hemodynamics in pulmonary hypertension.
SCH-58235 is a selective endothelin receptor antagonist that blocks endothelin-1 signaling to reduce pulmonary vascular resistance and improve hemodynamics in pulmonary hypertension. Used for Pulmonary arterial hypertension.
At a glance
| Generic name | SCH-58235 |
|---|---|
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Drug class | Endothelin receptor antagonist |
| Target | Endothelin receptor (ETA/ETB) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Endothelin-1 is a potent vasoconstrictor that plays a key role in the pathophysiology of pulmonary hypertension. By selectively antagonizing endothelin receptors, SCH-58235 promotes vasodilation and reduces the proliferation of pulmonary vascular smooth muscle cells. This mechanism helps restore normal pulmonary hemodynamics and improve exercise capacity in patients with pulmonary hypertension.
Approved indications
- Pulmonary arterial hypertension
Common side effects
- Headache
- Flushing
- Palpitations
- Peripheral edema
Key clinical trials
- Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma (EARLY_PHASE1)
- Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin (PHASE1)
- A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin (PHASE1)
- Cholesterol Lowering and Residual Risk in Diabetes, Type 1 (PHASE4)
- Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin (PHASE1)
- A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients (PHASE4)
- Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin (PHASE1)
- Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCH-58235 CI brief — competitive landscape report
- SCH-58235 updates RSS · CI watch RSS
- National Heart, Lung, and Blood Institute (NHLBI) portfolio CI